Business Context and Reporting Period
Company: Scinai Immunotherapeutics Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Date: February 17, 2026
Context: The filing announces the completion of the acquisition of Recipharm Israel Ltd. and the establishment of a strategic commercial collaboration with Recipharm.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a notification of a corporate event rather than a financial statement.
Material Changes
- Acquisition Completed: Scinai Immunotherapeutics Ltd. has completed the acquisition of Recipharm Israel Ltd.
- Strategic Collaboration: A strategic commercial collaboration with Recipharm has been established.
Guidance, Outlook, and Risks
The filing references a press release (Exhibit 99.1) for further details but does not contain specific management commentary, financial guidance, risk factors, or contingencies within the body of this Form 6-K text.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for details on the acquisition terms and collaboration scope.
- Verify the financial impact of the Recipharm Israel Ltd. acquisition on future balance sheets and cash flows.
- Confirm the strategic objectives and expected synergies of the commercial collaboration with Recipharm.